drugset / Trial / NCT00671567

Ramelteon in Adults With Chronic Insomnia

NCT00671567

Phase 3 Completed 848 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine the safety and efficacy of Ramelteon, once daily (QD), in adult subjects with chronic insomnia.

Timeline

Start
2002-12
Primary completion
2003-09
Completion
2003-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Ramelteon Unknown 8 mg Oral
Subject Ramelteon Unknown 16 mg Oral

Indications